Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Circulating miR-184 is a Potential Biomarker of Cardiac and Renal Damage in Anderson-Fabry Disease

ABSTRACT: Circulating miR-184 is a Potential Biomarker of Cardiac and Renal Damage in Anderson-Fabry Disease

PROVIDER: PRJNA680346 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13118562.fastq.gz	Fastqsanger.gz
	SRR13118563.fastq.gz	Fastqsanger.gz
	SRR13118564.fastq.gz	Fastqsanger.gz
	SRR13118565.fastq.gz	Fastqsanger.gz
	SRR13118566.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Circulating miR-184 is a Potential Biomarker of Cardiac and Renal Damage in Anderson-Fabry Disease

Project description:The clinical symptoms of Fabry disease are caused by progressive accumulation of unprocessed globotriaosylceramide metabolite within cells, inducing multiple organ damage. Enzyme replacement therapy (ERT) is the only strategy to restore enzymatic activity, but a reliable biomarker to assess treatment response does not exist. Here, we identify circulating miR-184 as a sensitive marker of response to ERT and of clinical outcome for cardiac and kidney involvement.

2021-11-06 | GSE162042 | GEO

Circulating miR-184 is a potential predictive biomarker of cardiac damage in Anderson-Fabry disease.

Project description:Enzyme replacement therapy (ERT) is a mainstay of treatment for Anderson-Fabry disease (AFD), a pathology with negative effects on the heart and kidneys. However, no reliable biomarkers are available to monitor its efficacy. Therefore, we tested a panel of four microRNAs linked with cardiac and renal damage in order to identify a novel biomarker associated with AFD and modulated by ERT. To this end, 60 patients with a definite diagnosis of AFD and on chronic ERT, and 29 age- and sex-matched healthy individuals, were enrolled by two Italian university hospitals. Only miR-184 met both conditions: its level discriminated untreated AFD patients from healthy individuals (c-statistic = 0.7522), and it was upregulated upon ERT (P < 0.001). On multivariable analysis, miR-184 was independently and inversely associated with a higher risk of cardiac damage (odds ratio = 0.86; 95% confidence interval [CI] = 0.76-0.98; P = 0.026). Adding miR-184 to a comprehensive clinical model improved the prediction of cardiac damage in terms of global model fit, calibration, discrimination, and classification accuracy (continuous net reclassification improvement = 0.917, P < 0.001; integrated discrimination improvement [IDI] = 0.105, P = 0.017; relative IDI = 0.221, 95% CI = 0.002-0.356). Thus, miR-184 is a circulating biomarker of AFD that changes after ERT. Assessment of its level in plasma could be clinically valuable in improving the prediction of cardiac damage in AFD patients.

| S-EPMC8665928 | biostudies-literature

Fabry nephropathy transcriptome

Project description:Fabry nephropathy (FN) is a rare disorder caused by mutations in the alpha-galactosidase A gene. In this study we aim at providing a framework allowing selection of biomarkers and drug-targets. Two independent Fabry Nephropathy cohorts (FA.NO and CH.RO) were subjected to RNAseq from archival kidney biopsies taken prior and up to 10 years of Enzyme Replacement Therapy. Four compartments were laser capture microdissected (glomeruli, proximal tubuli, distal tubuli and arteries). We found several pathways that were consistently altered and that these kidney compartments’ transcriptional landscapes can be leveraged in the search for drug-targets and biomarkers.

2023-07-17 | GSE178947 | GEO

Fabry nephropathy transcriptome

Project description:Fabry nephropathy transcriptome

| PRJNA741535 | ENA

Expression of transcriptome analysis of human fabry kidney organoid

Project description:Kidney organoids in vitro model enabled identification of a novel mechanism that may be used for the treatment of Fabry disease.

2021-01-16 | GSE164941 | GEO

Escherichia coli strain:184/2aE | isolate:184/2aE

Project description:Escherichia coli strain:184/2aE | isolate:184/2aE Genome sequencing

| PRJNA719994 | ENA

Glaesserella sp. 15-184 strain:15-184-2

Project description:Glaesserella sp. 15-184 strain:15-184-2 Genome sequencing

| PRJNA397816 | ENA

Podocyte injury in Fabry nephropathy

Project description:Podocyte injury in Fabry nephropathy

| PRJNA773084 | ENA

Transcriptomic analysis of microglia 4 month old ML4 Fabry and control mice

Project description:the study aims to describe the modifications occurring the microglia isolated from mouse models of 2 lysosomal storage diseases: Mucolipidosis type 4 and fabry disease.

2019-01-01 | GSE112895 | GEO

Sinorhizobium meliloti strain:184

Project description:Sinorhizobium meliloti 184 Resequencing

| PRJNA501482 | ENA